ES2654908T8 - Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica - Google Patents

Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica Download PDF

Info

Publication number
ES2654908T8
ES2654908T8 ES15151582.2T ES15151582T ES2654908T8 ES 2654908 T8 ES2654908 T8 ES 2654908T8 ES 15151582 T ES15151582 T ES 15151582T ES 2654908 T8 ES2654908 T8 ES 2654908T8
Authority
ES
Spain
Prior art keywords
treatment
diseases mediated
metabolic inflammation
thiazolidinedione analogues
thiazolidinedione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15151582.2T
Other languages
English (en)
Other versions
ES2654908T3 (es
Inventor
Gerard R. Colca
Rolf F. Kletzien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabolic Solutions Development Co LLC
Original Assignee
Metabolic Solutions Development Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Solutions Development Co LLC filed Critical Metabolic Solutions Development Co LLC
Application granted granted Critical
Publication of ES2654908T3 publication Critical patent/ES2654908T3/es
Publication of ES2654908T8 publication Critical patent/ES2654908T8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
ES15151582.2T 2006-03-16 2007-03-14 Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica Active ES2654908T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78289406P 2006-03-16 2006-03-16
US782894P 2006-03-16

Publications (2)

Publication Number Publication Date
ES2654908T3 ES2654908T3 (es) 2018-02-15
ES2654908T8 true ES2654908T8 (es) 2018-04-11

Family

ID=38328199

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15151582.2T Active ES2654908T3 (es) 2006-03-16 2007-03-14 Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica
ES07752982T Active ES2397944T3 (es) 2006-03-16 2007-03-14 Análogos de tiazolidindiona

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07752982T Active ES2397944T3 (es) 2006-03-16 2007-03-14 Análogos de tiazolidindiona

Country Status (15)

Country Link
US (4) US20090143442A1 (es)
EP (3) EP2001468B1 (es)
JP (2) JP5269758B2 (es)
KR (1) KR101475955B1 (es)
CN (1) CN101454005B (es)
AU (1) AU2007227581B2 (es)
CA (1) CA2646207C (es)
ES (2) ES2654908T3 (es)
HU (1) HUE035314T2 (es)
MX (2) MX356584B (es)
NZ (1) NZ571871A (es)
PL (2) PL2902026T3 (es)
RU (1) RU2445957C2 (es)
UA (1) UA96441C2 (es)
WO (1) WO2007109024A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2654908T3 (es) 2006-03-16 2018-02-15 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica
JP5149271B2 (ja) 2006-03-16 2013-02-20 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
EP2001470A2 (en) * 2006-03-16 2008-12-17 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues
AU2008301905B2 (en) 2007-09-14 2013-06-27 Cirius Therapeutics, Inc. Thiazolidinedione analogues for the treatment of hypertension
US8304441B2 (en) 2007-09-14 2012-11-06 Metabolic Solutions Development Company, Llc Thiazolidinedione analogues for the treatment of metabolic diseases
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
NZ619895A (en) 2008-08-12 2015-12-24 Zinfandel Pharmaceuticals Inc Method of identifying disease risk factors
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
MX2012006744A (es) * 2009-12-15 2012-07-30 Metabolic Solutions Dev Co Llc Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
KR20120103711A (ko) * 2009-12-15 2012-09-19 메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 신경퇴행성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
AU2014202074B2 (en) * 2009-12-15 2016-01-07 Cirius Therapeutics, Inc. PPAR-sparing thiazolidinediones and combinations for the treatment of neurodegenerative diseases
KR102029560B1 (ko) * 2009-12-15 2019-10-07 씨리우스 테라퓨틱스, 엘엘씨 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온염
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB2477743A (en) * 2010-02-10 2011-08-17 Argenta Therapeutics Ltd Enantiomers of 5-methyl-thiazolidine-2,4-dione glitazone compounds
JP2013532121A (ja) * 2010-04-19 2013-08-15 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー チアゾリジンジオン化合物のための新規な合成
NZ602883A (en) 2010-04-19 2014-09-26 Metabolic Solutions Dev Co Llc Novel synthesis for thiazolidinedione compounds
RU2594725C2 (ru) * 2010-08-10 2016-08-20 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Синтез соединений тиазолидиндиона
CN103180304B (zh) 2010-08-10 2017-02-15 奥克泰塔治疗有限责任公司 噻唑烷二酮化合物的合成方法
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012149083A1 (en) * 2011-04-28 2012-11-01 Metabolic Solutions Development Company, Llc Ppar-sparing thiazolidinediones for the treatment of kidney related diseases
KR20130015932A (ko) * 2011-08-05 2013-02-14 연세대학교 산학협력단 저용량의 치아졸리딘다이온을 포함하는 알츠하이머 병 치료용 약학조성물
KR101501375B1 (ko) 2012-09-21 2015-03-10 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
WO2014046474A2 (ko) * 2012-09-21 2014-03-27 가톨릭대학교 산학협력단 메트포민을 유효성분으로 함유하는 염증성 장질환의 예방 또는 치료용 조성물
MX2015007479A (es) * 2012-12-11 2015-09-04 Metabolic Solutions Dev Co Llc Tiazolidindionas ahorradoras de receptores activados proliferadores de peroxisoma (ppar) y combinaciones para el tratamiento de enfermedades neurodegenerativas.
US8969581B2 (en) 2013-03-14 2015-03-03 Deuterx, Llc 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
RU2687490C2 (ru) 2013-07-22 2019-05-14 МЕТАБОЛИК СОЛЮШИНС ДЕВЕЛОПМЕНТ КО., ЭлЭлСи Ppar-поддерживающие соединения для лечения метаболических заболеваний
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
LT3125888T (lt) 2014-04-02 2018-07-10 Minoryx Therapeutics S.L. 2,4-tiazolidindiono dariniai, skirti centrinės nervų sistemos sutrikimų gydymui
CA3044364A1 (en) 2016-12-01 2018-06-07 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
GB202210503D0 (en) 2022-07-18 2022-08-31 Univ Court Univ Of Glasgow Materials and methods for treatment of chronic myeloid leukemia (CML)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
WO1985004170A1 (en) * 1984-03-21 1985-09-26 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and medicinal composition containing same
WO1986002073A1 (en) 1984-10-03 1986-04-10 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, process for their preparation, and pharmaceutical composition containing same
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US5167228A (en) * 1987-06-26 1992-12-01 Brigham And Women's Hospital Assessment and modification of endogenous circadian phase and amplitude
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5441971A (en) * 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
ATE202352T1 (de) * 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
NO302471B1 (no) 1991-12-26 1998-03-09 Sankyo Co Tiazolidinforbindelser og farmasöytisk preparat
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
CZ283339B6 (cs) * 1993-09-15 1998-03-18 Sankyo Company Limited Použití thiazolidinových derivátů pro výrobu léčivého přípravku pro léčení zhoršené tolerance glukosy pro zabránění nebo zpoždění nástupu diabetes mellitus nezávislé na inzulinu
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5798375A (en) 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
GB0030845D0 (en) * 2000-12-18 2001-01-31 Smithkline Beecham Plc Novel treatment
HUP0400091A2 (hu) 2001-04-26 2004-06-28 Léciva, a.s. Eljárás antidiabetikus hatású pioglitazon előállítására
EP1690538A4 (en) * 2003-12-02 2009-02-25 Shionogi & Co ISOXAZOLE DERIVATIVE AGONISTIC ACTION AGAINST PEROXISOM PROLIFERATOR ACTIVATED RECEPTOR
JP5149271B2 (ja) * 2006-03-16 2013-02-20 メタボリック ソリューションズ ディベロップメント カンパニー， エルエルシー 高血圧症を処置するためならびに脂質を下げるためのチアゾリジンジオン類似体
EP2001470A2 (en) 2006-03-16 2008-12-17 Metabolic Solutions Development Company Combination therapies of thiazolidinedione analogues
ES2654908T3 (es) 2006-03-16 2018-02-15 Metabolic Solutions Development Company Llc Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica
AU2008301905B2 (en) 2007-09-14 2013-06-27 Cirius Therapeutics, Inc. Thiazolidinedione analogues for the treatment of hypertension

Also Published As

Publication number Publication date
ES2397944T3 (es) 2013-03-12
US9155729B2 (en) 2015-10-13
AU2007227581B2 (en) 2012-11-08
EP2001468A2 (en) 2008-12-17
WO2007109024A2 (en) 2007-09-27
PL2902026T3 (pl) 2018-03-30
EP2902026A1 (en) 2015-08-05
US20150190385A1 (en) 2015-07-09
MX2008011871A (es) 2009-02-10
PL2001468T3 (pl) 2013-03-29
CN101454005A (zh) 2009-06-10
WO2007109024A3 (en) 2007-11-15
KR101475955B1 (ko) 2014-12-23
JP5269758B2 (ja) 2013-08-21
US20120015982A1 (en) 2012-01-19
EP2902026B1 (en) 2017-10-04
HUE035314T2 (en) 2018-05-02
KR20090037381A (ko) 2009-04-15
JP2013100371A (ja) 2013-05-23
NZ571871A (en) 2011-07-29
CN101454005B (zh) 2013-01-02
ES2654908T3 (es) 2018-02-15
JP2009530283A (ja) 2009-08-27
CA2646207A1 (en) 2007-09-27
CA2646207C (en) 2016-01-19
US20130203820A1 (en) 2013-08-08
AU2007227581A1 (en) 2007-09-27
US20090143442A1 (en) 2009-06-04
EP2001468B1 (en) 2012-10-31
RU2445957C2 (ru) 2012-03-27
RU2008140943A (ru) 2010-04-27
US8389556B2 (en) 2013-03-05
MX356584B (es) 2018-06-05
UA96441C2 (ru) 2011-11-10
EP2486926A1 (en) 2012-08-15

Similar Documents

Publication Publication Date Title
ES2654908T8 (es) Análogos de tiazolidindiona para el tratamiento de enfermedades mediadas por una inflamación metabólica
CY2020032I1 (el) Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια
CR11019A (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
BRPI0817096A2 (pt) análogos de tiazolidinodiona para o tratamento de hipertensão
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
CR10245A (es) "nuevas combinaciones terapéuticas para el tratamiento de la depresión"
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
ES2525801T8 (es) Composiciones y métodos para la prevención y el tratamiento de enfermedades autoinmunes
BRPI0716435A2 (pt) Compostos para o tratamento de doenças proliferativas
IL200368A0 (en) Treatment of diseases characterized by inflammation
IL186749A0 (en) Dihydrothienopyrimidines for the treatment of inflammatory diseases
BRPI0919004A2 (pt) composto de multiheteroarila como inibidores de h-pgds e sua utilização para o tratamento de doenças mediadas por prostaglandina d2
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"
FI20095600A (fi) Koostumus ihosairauksien hoitoa varten
IL200091A (en) Kittensan to treat infectious diseases of the nail
LTC2066352I2 (lt) Išsėtinės sklerozės (MS) gydymas kampatu-1H
ES2399651T8 (es) Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena
BRPI0914454A2 (pt) "composição para o tratamento do tecido epitelial"
BRPI0923377A2 (pt) Derivados de 1-amino-alquilciclohexano para o tratamento de doenças mediadas por mastócitos
ZA200905364B (en) Treatment of diseases characterized by inflammation
BRPI0912890A2 (pt) composição farmacêutica para o tratamento de ejaculação precoce